Geoff Meacham
Stock Analyst at Citigroup
Total Price Targets
21
Stocks Covered
14
Sectors
Healthcare
Most Recent
Aug 1, 2025
Notable Calls (Last 12 Months)
Stocks Covered by Geoff Meacham
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | $650.00 | $703.72 | -7.6% | 2 | Aug 1, 2025 |
| MRNA | Moderna, Inc. | $40.00 | $44.65 | -10.4% | 1 | Aug 1, 2025 |
| BIIB | Biogen Inc. | $160.00 | $186.69 | -14.3% | 2 | Feb 12, 2025 |
| ABBV | AbbVie Inc. | $226.00 | $206.29 | +9.6% | 2 | Oct 31, 2024 |
| LYEL | Lyell Immunopharma, Inc. | $1.00 | $20.89 | -95.2% | 1 | Oct 30, 2024 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $10.00 | $16.04 | -37.6% | 1 | Oct 23, 2024 |
| VRTX | Vertex Pharmaceuticals Incorporated | $541.00 | $425.06 | +27.3% | 2 | Oct 14, 2024 |
| LLY | Eli Lilly and Company | $1150.00 | $961.67 | +19.6% | 3 | Aug 9, 2024 |
| MRK | Merck & Co., Inc. | $145.00 | $111.89 | +29.6% | 2 | Jul 31, 2024 |
| GILD | Gilead Sciences, Inc. | $95.00 | $132.04 | -28.1% | 1 | Sep 8, 2023 |
| PFE | Pfizer Inc. | $70.00 | $26.38 | +165.4% | 1 | Mar 12, 2022 |
| BMRN | BioMarin Pharmaceutical Inc. | $120.00 | $54.20 | +121.4% | 1 | Jan 10, 2022 |
| AMGN | Amgen Inc. | $255.00 | $328.69 | -22.4% | 1 | Jan 5, 2022 |
| BMY | Bristol-Myers Squibb Company | $78.00 | $58.22 | +34.0% | 1 | Jul 27, 2021 |
Recent Activity
- Aug 1, 2025— Set$40.00price target onMRNA(Moderna, Inc.)
- Aug 1, 2025— Set$650.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Feb 12, 2025— Set$160.00price target onBIIB(Biogen Inc.)
- Oct 31, 2024— Set$226.00price target onABBV(AbbVie Inc.)
- Oct 30, 2024— Set$1.00price target onLYEL(Lyell Immunopharma, Inc.)
- Oct 23, 2024— Set$10.00price target onAMLX(Amylyx Pharmaceuticals, Inc.)
- Oct 18, 2024— Set$195.00price target onABBV(AbbVie Inc.)
- Oct 14, 2024— Set$541.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Aug 9, 2024— Set$1150.00price target onLLY(Eli Lilly and Company)
- Aug 2, 2024— Set$805.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Jul 31, 2024— Set$145.00price target onMRK(Merck & Co., Inc.)
- Jun 3, 2024— Set$913.00price target onLLY(Eli Lilly and Company)
- Sep 8, 2023— Set$95.00price target onGILD(Gilead Sciences, Inc.)
- Mar 28, 2022— Set$225.00price target onBIIB(Biogen Inc.)
- Mar 26, 2022— Set$315.00price target onLLY(Eli Lilly and Company)
- Mar 12, 2022— Set$70.00price target onPFE(Pfizer Inc.)
- Jan 10, 2022— Set$120.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Jan 5, 2022— Set$255.00price target onAMGN(Amgen Inc.)
- Nov 2, 2021— Set$275.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Oct 29, 2021— Set$86.00price target onMRK(Merck & Co., Inc.)
Frequently Asked Questions
Who is Geoff Meacham?
Geoff Meacham is a stock analyst at Citigroup covering 14 stocks primarily in Healthcare. They have issued 21 price targets since Jul 27, 2021.
What stocks does Geoff Meacham cover?
Geoff Meacham currently covers 14 stocks, including LLY, REGN, BIIB, ABBV, VRTX.
What is Geoff Meacham's latest price target?
Geoff Meacham's most recent price target was $40.00 on MRNA (Moderna, Inc.), set on Aug 1, 2025.
What is Geoff Meacham's highest price target?
Geoff Meacham's highest issued price target is $1150.00 on LLY, set on Aug 9, 2024.
More Analysts at Citigroup
Coverage based on publicly published price targets. Not investment advice.